StockNews.com Initiates Coverage on OpGen (NASDAQ:OPGN)

Investment analysts at StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Stock Up 0.7 %

OpGen stock opened at $1.38 on Thursday. OpGen has a 12-month low of $0.53 and a 12-month high of $9.90. The firm’s fifty day moving average price is $1.02 and its 200 day moving average price is $1.60.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.